Management of toxicities of immune checkpoint inhibitors. [electronic resource]
Producer: 20160706Description: 51-60 p. digitalISSN:- 1532-1967
- Adrenal Cortex Hormones -- therapeutic use
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Humanized -- adverse effects
- Antilymphocyte Serum -- therapeutic use
- Antineoplastic Agents -- adverse effects
- CTLA-4 Antigen -- antagonists & inhibitors
- Carcinoma, Renal Cell -- drug therapy
- Chemical and Drug Induced Liver Injury -- drug therapy
- Colitis -- chemically induced
- Cyclosporine -- therapeutic use
- Diarrhea -- chemically induced
- Drug Eruptions -- drug therapy
- Humans
- Immunosuppressive Agents -- therapeutic use
- Infliximab -- therapeutic use
- Ipilimumab
- Kidney Neoplasms -- drug therapy
- Lung Neoplasms -- drug therapy
- Melanoma -- drug therapy
- Mycophenolic Acid -- analogs & derivatives
- Neoplasms -- drug therapy
- Nivolumab
- Pituitary Diseases -- chemically induced
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Skin Neoplasms -- drug therapy
- Tacrolimus -- therapeutic use
- Thyroiditis -- chemically induced
No physical items for this record
Publication Type: Journal Article; Review
There are no comments on this title.
Log in to your account to post a comment.